Clinical Trial Update: Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial [Phase 2]

View source ↗

Summary

The Phase 2 VENT trial evaluating fezolinetant to improve vasomotor symptoms in breast cancer patients on endocrine therapy has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Ductal Carcinoma in Situ

Drugs mentioned

• Fezolinetant (fezolinetant)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 2 | Status: TERMINATED